These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cross-sectional study of prevalence and risk factors, and a cost-effectiveness evaluation of screening and preventive treatment strategies for latent tuberculosis among migrants in Singapore. Lim VW; Wee HL; Lee P; Lin Y; Tan YR; Tan MX; Lin LW; Yap P; Chee CB; Barkham T; Lee V; Chen M; Ong RT BMJ Open; 2021 Jul; 11(7):e050629. PubMed ID: 34266845 [TBL] [Abstract][Full Text] [Related]
6. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area. Li J; Yip BHK; Leung C; Chung W; Kwok KO; Chan EYY; Yeoh E; Chung P PLoS One; 2018; 13(1):e0189531. PubMed ID: 29293514 [TBL] [Abstract][Full Text] [Related]
7. Modeling the Cost-Effectiveness of Latent Tuberculosis Screening and Treatment Strategies in Recent Migrants to a Low-Incidence Setting. Dale KD; Abayawardana MJ; McBryde ES; Trauer JM; Carvalho N Am J Epidemiol; 2022 Jan; 191(2):255-270. PubMed ID: 34017976 [TBL] [Abstract][Full Text] [Related]
8. A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries. Zammarchi L; Casadei G; Strohmeyer M; Bartalesi F; Liendo C; Matteelli A; Bonati M; Gotuzzo E; Bartoloni A; BMC Health Serv Res; 2015 Sep; 15():412. PubMed ID: 26399233 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries. Kowada A Travel Med Infect Dis; 2016; 14(5):489-498. PubMed ID: 27238907 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman. Al Abri S; Kowada A; Yaqoubi F; Al Khalili S; Ndunda N; Petersen E Int J Infect Dis; 2020 Mar; 92S():S72-S77. PubMed ID: 32171953 [TBL] [Abstract][Full Text] [Related]
11. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. Haukaas FS; Arnesen TM; Winje BA; Aas E Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of pre-entry active tuberculosis and post-entry latent tuberculosis screening in new entrants to the UK: a retrospective, population-based cohort study. Berrocal-Almanza LC; Harris R; Lalor MK; Muzyamba MC; Were J; O'Connell AM; Mirza A; Kon OM; Lalvani A; Zenner D Lancet Infect Dis; 2019 Nov; 19(11):1191-1201. PubMed ID: 31471131 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries. Kowada A; Takasaki J; Kobayashi N J Hosp Infect; 2015 Feb; 89(2):99-108. PubMed ID: 25559158 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the latent tuberculosis screening program for migrants in Stockholm Region. Shedrawy J; Deogan C; Öhd JN; Hergens MP; Bruchfeld J; Jonsson J; Siroka A; Lönnroth K Eur J Health Econ; 2021 Apr; 22(3):445-454. PubMed ID: 33559787 [TBL] [Abstract][Full Text] [Related]
15. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Sadatsafavi M; Marra C; Marra F; Moran O; FitzGerald JM; Lynd L Value Health; 2013; 16(1):66-75. PubMed ID: 23337217 [TBL] [Abstract][Full Text] [Related]
16. Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. Patel AR; Campbell JR; Sadatsafavi M; Marra F; Johnston JC; Smillie K; Lester RT BMJ Open; 2017 Sep; 7(9):e015108. PubMed ID: 28918407 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection. Zenner D; Hafezi H; Potter J; Capone S; Matteelli A Int J Tuberc Lung Dis; 2017 Sep; 21(9):965-976. PubMed ID: 28826445 [TBL] [Abstract][Full Text] [Related]
18. A Step toward Tuberculosis Elimination in a Low-Incidence Country: Successful Diagnosis and Treatment of Latent Tuberculosis Infection in a Refugee Clinic. Rennert-May E; Hansen E; Zadeh T; Krinke V; Houston S; Cooper R Can Respir J; 2016; 2016():7980869. PubMed ID: 27445565 [TBL] [Abstract][Full Text] [Related]
19. Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country. Bourgarit A; Baron G; Breton G; Tattevin P; Katlama C; Allavena C; Campa P; Ravaud P; Lortholary O; Carcelain G; Ann Am Thorac Soc; 2015 Aug; 12(8):1138-45. PubMed ID: 26213798 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Diel R; Nienhaus A; Loddenkemper R Chest; 2007 May; 131(5):1424-34. PubMed ID: 17494792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]